465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Vitamin D Obesity Disorder	Agricultural University of Athens	P4	BB (64)
Zovaglutide Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P3	BB (64)
Desflurane Obesity Disorder	Medical University of Gdansk	P4	B (63)
Hrs-7535 Obesity Disorder	Shandong Suncadia Medicine Co., Ltd.	P3	B (63)
Mdr-001 Obesity Disorder	MindRank AI Ltd	P3	B (63)
Nepenthe Obesity Disorder	Kirsehir Ahi Evran Universitesi	P4	B (63)
Pioglitazone Obesity Disorder	Mayo Clinic	P4	B (63)
Serostim Obesity Disorder	Columbia University	P4	B (63)
Setmelanotide Obesity Disorder	Massachusetts General Hospital	P3	B (63)
Cefadroxil Anhydrous Obesity Disorder	Mayo Clinic	P4	B (62)
Cephalexin Obesity Disorder	Mayo Clinic	P4	B (62)
ct-868 Obesity Disorder	Carmot Therapeutics, Inc.	P2	B (62)
Enoxaparin Obesity Disorder	University College Dublin	P4	B (62)
Metoclopramide Obesity Disorder	Mater Misericordiae University Hospital	P4	B (62)
Mirabegron Obesity Disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P4	B (62)
Secukinumab Obesity Disorder	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P4	B (62)
Tadalafil Obesity Disorder	Philip Kern	P4	B (62)
Valsartan Obesity Disorder	ARKAY Therapeutics	P4	B (62)
CPX101 Obesity Disorder	Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.	P2	B (61)
Fentanyl Obesity Disorder	IVO JURISIC	P4	B (61)
Glucose, Anhydrous Obesity Disorder	Columbia University	P4	B (61)
hs-20094 Obesity Disorder	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (61)
Losartan Obesity Disorder	RenJi Hospital	P4	B (61)
Misoprostol Obesity Disorder	University of Texas at Austin	P4	B (61)
xw003 Obesity Disorder	Hangzhou Sciwind Biosciences Co., Ltd.	P3	B (61)
zt002 Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P2	B (61)
Amino Acids,Essential Obesity Disorder	University of Colorado, Denver	P3	B (60)
Aphd-012 Obesity Disorder	Aphaia Pharma US LLC	P2	B (60)
Apiguard Obesity Disorder	Centro Universitario de Ciencias de la Salud, Mexico	P4	B (60)
Bazedoxifene Obesity Disorder	VA Office of Research and Development	P4	B (60)
Capecitabine Obesity Disorder	Ikaria Bioscience Pty Ltd	P4	B (60)
Contrave Obesity Disorder	The Royal's Institute of Mental Health Research	P4	B (60)
Estrogens, Conjugated Obesity Disorder	VA Office of Research and Development	P4	B (60)
hm15275 Obesity Disorder	Hanmi Pharmaceutical Company Limited	P2	B (60)
hu6 Obesity Disorder	Rivus Pharmaceuticals, Inc.	P2	B (60)
Mirikizumab Obesity Disorder	Eli Lilly and Company	P3	B (60)
Moxonidine Obesity Disorder	Vanderbilt University Medical Center	P4	B (60)
Quinine Obesity Disorder	Universitaire Ziekenhuizen KU Leuven	P4	B (60)
zt006 Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P2	B (60)
Acarbose Obesity Disorder	Empros Pharma AB	P4	B (59)
Dulaglutide Obesity Disorder	Ali Aminian	P4	B (59)
Marcaine Obesity Disorder	University of North Carolina, Chapel Hill	P4	B (59)
Qsymia Obesity Disorder	Alvogen Korea	P4	B (59)
Simvastatin Obesity Disorder	Eli Lilly and Company	P4	B (59)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Obesity Disorder	Tanta University	P4	B (58)
Caffeine Obesity Disorder	Boehringer Ingelheim	P3	B (58)
cx11 Obesity Disorder	Corxel Pharmaceuticals	P3	B (58)
Doravirine Obesity Disorder	José Antonio Mata Marín	P4	B (58)
Elecoglipron Obesity Disorder	AstraZeneca	P3	B (58)
Eloralintide Obesity Disorder	Eli Lilly and Company	P3	B (58)

Showing 51 to 100 of 465 assets

PreviousPage 2 of 10Next